Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/18914
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Alifrangis, C. | - |
dc.contributor.author | Carter, P. | - |
dc.contributor.author | Cereser, B. | - |
dc.contributor.author | Chandrasinghe, P. | - |
dc.contributor.author | Belluz, L.D.B. | - |
dc.contributor.author | Lim, E. | - |
dc.contributor.author | Moderau, N. | - |
dc.contributor.author | Poyia, F. | - |
dc.contributor.author | Tabassum, N. | - |
dc.contributor.author | Zhang, H. | - |
dc.contributor.author | Krell, J. | - |
dc.contributor.author | Stebbing, J. | - |
dc.date.accessioned | 2018-07-04T08:44:46Z | - |
dc.date.available | 2018-07-04T08:44:46Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Oncotarget.2018;9(16):12805-12811 | en_US |
dc.identifier.issn | 1949-2553 (Electronic) | - |
dc.identifier.issn | 1949-2553 (Linking) | - |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/18914 | - |
dc.description | Indexed In MEDLINE | en_US |
dc.description.abstract | In this study we utilized data on patient responses to guided treatments, and we evaluated their benefit for a non-small cell lung cancer cohort. The recommended therapies used were predicted using tumor molecular profiles that involved a range of biomarkers but primarily used immunohistochemistry markers. A dataset describing 91 lung non-small cell lung cancer patients was retrospectively split into two. The first group's drugs were consistent with a treatment plan whereby all drugs received agreed with their tumor's molecular profile. The second group each received one or more drug that was expected to lack benefit. We found that there was no significant difference in overall survival or mortality between the two groups. Patients whose treatments were predicted to be of benefit survived for an average of 402 days, compared to 382 days for those that did not (P = 0.7934). In the matched treatment group, 48% of patients were deceased by the time monitoring had finished compared to 53% in the unmatched group (P = 0.6094). The immunohistochemistry biomarker for the ERCC1 receptor was found to be a marker that could be used to predict future survival; ERCC1 loss was found to be predictive of poor survival. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Impact Journals | en_US |
dc.subject | Cancer treatments | en_US |
dc.title | Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments | en_US |
dc.type | Article | en_US |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
oncotarget-09-12805.pdf | 2.14 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.